Informa helps businesses and professionals in hundreds of ways.

Our international portfolio of live events, world-leading research publications, and innovative digital services provide specialists with the knowledge and connections they need to thrive.

Antibody Engineering & Therapeutics Europe
1 - 3 June, 2027
Congress CenterBasel Switzerland

Main Conference: 1 - 3 June, 2027 | Congress Center, Basel, Switzerland

ADCs & Bioconjugate Track

Accelerating Antibody‑Drug Conjugate Innovation from Discovery to Clinical Impact

Why Attend the ADCs & Bioconjugates Track?

ADCs are among the most complex and promising biologic modalities in development today. Success depends on integrating antibody engineering, chemistry, payload design, pharmacology, and clinical strategy.

What This Track Covers

The co-located ADCs & Bioconjugates Track delivers over 3 full days of content, including keynotes, 30+ speakers and 5 half-day sessions, each featuring 6 expert speakers from leading pharmaceutical companies, biotech innovators, and academic research institutions.

Bispecific ADCs & AOCs for Improved Delivery

Novel Payloads & ADCs with New Mechanism of Action

High DAR Technologies & Predicting ADC Properties (Tox, Th. Window)

Beyond Topo1 Inhibitors & Finding New Validated Targets for ADCs

Phase 2 & 3 Clinical Updates or Deep Data/Informatics for ADCs

This track is specifically designed for professionals who:

  • Are developing or optimising ADC or bioconjugate programmes
  • Work at the interface of antibody engineering and chemistry
  • Need to improve therapeutic index, safety, or clinical translation
  • Want to understand why some ADCs succeed while others fail
  • Are responsible for strategic R&D or pipeline decisions